Key result
Statin use is linked to ~27% lower risk of new-onset CKD in older adults.
Cohort (n=2,455)
Yes
Answers are grounded in this paper and cite their sources.
Purpose: The effects of statins on renal outcomes have already been studied in patients with chronic kidney disease (CKD); however, data on the general population are limited. We evaluated the association between statin use and risk of CKD in community-dwelling older people in Shanghai, China. Patients and Methods: This registry-based cohort study was conducted in four communities in four districts in Shanghai. Participants with an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m 2 in 2016 were eligible for the study, and new-onset CKD in 2017, 2018, and 2019 was recorded. Poisson generalized linear models were conducted to examine the relationships among statin therapy, dyslipidemia, and CKD; linear mixed-effects models were conducted to examine the relationships between statin therapy and changes in eGFR. All analyses were performed with both conventional adjustment and propensity score-matching methods. Results: Of the study cohort of 2455 participants (41.1% men; average age, 68.06 years), 624 (25.4%) were treated with stains. Two propensity score-matched cohorts of 604 participants each were analyzed (statin users and nonusers). Statin use was significantly associated with a decreased risk of new-onset CKD with hazard ratios (HRs) and 95% confidence intervals (CIs) of 0.73 (0.59 to 0.91) ( p < 0.01) in the unmatched cohort and 0.75 (0.59 to 0.97) ( p =0.02) in the matched cohort. There were significant differences in the eGFR decline between statin users and nonusers from baseline to 3 years in the unmatched and matched cohorts (both p < 0.05). In addition, both statin users and nonusers with dyslipidemia experienced more new-onset CKD (both p < 0.05). Conclusion: Statin use was significantly associated with a decreased risk of new-onset CKD and a slower decline in eGFR in community-dwelling older people. Meanwhile, dyslipidemia was a risk factor for CKD progression among both statin users and nonusers.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2022) conducted a cohort in Chronic kidney disease risk in community-dwelling older adults (n=2,455). Statin use vs. Statin nonusers was evaluated on New-onset chronic kidney disease (CKD) (HR 0.73, 95% CI 0.59-0.91, p=<0.01). Statin use was associated with a reduced risk of new-onset CKD in older adults.
Synapse has enriched 10 related papers. Consider them for comparative context: